Would you feel comfortable using a combination treatment of a GLP-1 receptor agonist and a SGLT-2 inhibitor for a patient who has not reached goal? Follow the link to respond.
Read More »Production Assistant, Diabetes In Control
Future Use of Technology in Outpatient Care Part 3
In this week's Homerun Slides, asking the question of how to translate knowledge and implications of pathophysiology, progression, and diabetes complications to the prevention, early diagnosis and optimal treatment of diabetes and its complications.
Read More »International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #130: Pathogenesis of Type 2 Diabetes Mellitus Part 1
Normal glucose homeostasis: Any discussion of the pathogenesis of type 2 diabetes mellitus (T2DM) must start with a review of mechanisms involved in the maintenance of normal glucose homeostasis in the basal o postabsorptive state (10–12-h overnight fast) and following ingestion of a typical mixed meal. In the postabsorptive state the great majority of total body glucose disposal takes place in insulin independent tissues.
Read More »Relationship Between HbA1c and Stroke Risk
New meta-analysis striving to expand on the notion that glycemic control and stroke risk are closely associated.
Read More »Sotagliflozin (Zynquista): A Novel SGLT Medication
Sotagliflozin to be reviewed by the FDA as possible oral adjunct for people with insulin-treated type 1 diabetes.
Read More »Another Look at Blood Pressure Targets for People with Type 2 Diabetes
Discrepancies prompt additional analyses of ACCORD-BP and SPRINT studies to determine best blood pressure target for those with diabetes.
Read More »Risk of Euglycemic Diabetic Ketoacidosis After Initiation of an SGLT-2 Inhibitor
Detection of euglycemic ketoacidosis could be a challenge for physicians since this condition can mask an underlying diabetic ketoacidosis.
Read More »Text Messages That Will Help Patients Get Glycemic Control
With more than 8 trillion text messages sent worldwide every year, self-management support for blood glucose (SMS4BG) has potential to help improve glycemic management of patients who have diabetes.
Read More »Cost Effectiveness of Continuous Glucose Monitoring in Type 1 Diabetes
Data from DIAMOND trial to help determine if CGM helps those with consistently high glucose.
Read More »Clinical Case Vignette: Macronutrients
Mr. Carlson is a man, 52-years of age. He is Caucasian and works as a grocery store manager. His labs show that they were significant for elevated random plasma glucose 166 mg/dL, A1C 7.6% and elevated lipids (TG=175 mg/dL, LDL 148 mg/dL, HDL 38 mg/dL, total cholesterol 221 mg/dL). His physical exam is notable for central abdominal obesity (waist circumference 42”), BP 147/91, HR 72, RR 18, BMI 36 kg/m2, but otherwise normal. He is started on metformin and a dietitian is recommended. The dietitian discusses with him the benefits of medical nutrition therapy on weight, glycemic control, blood pressure, lipid profile, and overall wellbeing. Which following statement regarding macronutrients is true? A. The ratio of carbohydrates, protein and fat is the same for all patients. B. Total calories consumed per day is the key strategy for achieving glycemic control. C. Reduced intake of trans fat lowers the HDL and raises the LDL. D. Saturated fat should be less than 7% of total calories. Follow the link for the answer.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.